Loading organizations...
§ Private Profile · Philadelphia, PA, USA
Biotech company developing novel immunotherapy platform for solid tumors, creating universal in vivo CAR-T treatments.
Dispatch Bio is a biotechnology company based in San Francisco and Philadelphia that develops a novel in vivo CAR-T immunotherapy platform designed to create universal treatments for solid tumors. The enterprise utilizes a two-pronged approach incorporating viral vectors to target cancers such as lung, breast, colon, and pancreatic, while specifically addressing the clinical challenges in distinguishing malignant cells from healthy tissue. Operating with approximately 60 employees, the firm emerged from stealth in 2025 and plans to initiate its initial Phase 1 clinical trials in 2026. The organization has raised $216 million in seed and Series A funding from a syndicate of prominent investors including Arch Venture Partners, Bristol Myers Squibb, and the Parker Institute for Cancer Immunotherapy. Dispatch Bio was founded in 2022 by scientific co-founders Carl June, Chris Garcia, Andy Minn, and Kole Roybal.
Dispatch Bio has raised $220.0M across 1 funding round.
Dispatch Bio has raised $220.0M in total across 1 funding round.
Dispatch Bio has raised $220.0M in total across 1 funding round.
Dispatch Bio's investors include ARCH Venture Partners, Sean Parker, Atlas Venture, Nextech Invest, Alexandria Venture Investments, Bristol Myers Squibb, Stanford University, University of Pennsylvania.
Dispatch Bio has raised $220.0M across 1 funding round. Most recently, it raised $220.0M Series A in July 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2025 | $220M Series A | ARCH Venture Partners, Sean Parker | Atlas Venture, Nextech Invest, Alexandria Venture Investments, Bristol Myers Squibb, Stanford University, University OF Pennsylvania | Announced |
Dispatch Bio is a biotechnology company founded in 2022 to develop a universal immunotherapy treatment for solid tumors, which represent the majority of cancers and have proven resistant to existing immunotherapies.[1][2][3] The company builds the Flare platform, a first-in-class system that uses an engineered viral vector to tag tumor cells with a novel universal antigen called "Flare," while disrupting the immune-suppressive tumor microenvironment; this beacon then guides specially engineered immune cells, such as CAR-T, to precisely eliminate cancer cells without harming healthy tissue.[1][2][3][4] Dispatch serves cancer patients with solid tumors like lung, breast, colon, gastric, esophageal, and pancreatic, addressing key challenges: lack of tumor-specific targets and immunosuppressive barriers.[1][3][5] With $216 million raised—including from ARCH Venture Partners, Parker Institute for Cancer Immunotherapy (PICI), Bristol Myers Squibb, University of Pennsylvania, and Stanford—Dispatch emerged from stealth in July 2025 under CEO Sabah Oney, Ph.D., planning its first clinical trial in 2026 for tough-to-treat solid tumors.[2][3][5]
Dispatch Bio originated from a pivotal collaboration sparked at a PICI retreat, where scientific co-founders Carl June, M.D. (University of Pennsylvania cell therapy pioneer), Chris Garcia, Ph.D. (Stanford), Kole Roybal, Ph.D. (UCSF), and Andy Minn, M.D., Ph.D. (Memorial Sloan Kettering immuno-oncology chair), along with PICI founder Sean Parker, debated solutions to solid tumor immunotherapy hurdles.[1][3][4] Established in 2022 by PICI and ARCH Venture Partners, the company converged technologies from these labs to create the Flare platform, with operations in Philadelphia and San Francisco for access to top researchers.[1][2][3] Early traction came from stealth-mode development, culminating in a $216 million public launch in July 2025, backed by a world-class team including CEO Sabah Oney and the co-founders, positioning Dispatch to pursue a "universal cure" for solid tumors.[1][2][5]
Dispatch rides the wave of next-generation immunotherapy, merging viral vectors, synthetic antigens, and CAR-T to crack solid tumors—where blood cancer successes like CAR-T have faltered due to targeting and microenvironment issues.[1][3][4] Timing is ideal post-2025 funding surge, amid market forces like rising solid tumor incidence (e.g., lung, breast), immunotherapy resistance, and demand for "off-the-shelf" universal therapies over patient-specific ones.[2][5] By enabling tumor-agnostic treatments, Dispatch influences the ecosystem, potentially expanding curative potential to 90% of cancers, accelerating academic-commercial translation via PICI networks, and combating resistance mechanisms.[3][4]
Dispatch Bio stands at the cusp of transforming solid tumor care with its Flare platform entering clinic in 2026, leveraging $216M and star scientists for Phase 1 data soon and Phase 2 toward accelerated approval.[2][5] Trends like AI-optimized vectors, combo immunotherapies, and regulatory fast-tracks for tumor-agnostic drugs will propel it, potentially yielding a platform blockbuster if efficacy holds across indications.[3][5] Its influence could evolve from stealth innovator to ecosystem leader, redefining "universal" cancer cures and drawing more capital to in vivo CAR-T hybrids—echoing its bold launch promise of a tumor-free world.[1][4]